Cancer Therapeutics.

Cancer Therapeutics.NKTR-102nectar developed NKTR-102, a PEGylated form of irinotecan, Nektar Nektar using its advanced polymer conjugate technology platform the first patient in Phase 2 Clinical Trial Of NKTR-102 in ovarian cancer dosed. NKTR-102 is the first oncolytic that leverages Nektar polymer conjugate technology. With a proprietary approach that directly conjugates the drug is a unique polymer architecture nectar the first company created a PEGylated small molecule with a unique pharmacokinetic profile therapeutic efficacy therapeutic efficacy in patients.

About the NKTR-102 phase 2 study designsthe NKTR-102 phase 2 randomized trial evaluating the efficacy and safety of NKTR-102 monotherapy versus irinotecan in second-line colorectal cancer patients with KRAS mutant gene the primary endpoint this. Placebo-controlled trial will be a clinically meaningful improvement in progression-free survival to standard irinotecan monotherapy compared. It is estimated that up to 45 percent of colorectal cancer cases have to respond mutation in the KRAS gene and not on EGFR inhibitors, such as cetuximab.As the President Barack Obama that healthcare system statement signed into law in the last year, was his big aim, cutting the cost of Medicare. The Congressional Budget Office estimates savings reduce U.S. Deficits carried $ 143,000.

Other Posts From Category "healthcare":

Related Posts